Intestinal Neoplasm

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC… (full text at CIViC)

PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitiv… (full text at CIViC)

PMID 24894453 · Cho et al., 2014 · Open in CIViC

Oncogenic somatic EGFR mutations found in colorectal cancer samples were tested for sensitivity to EGFR inhibitors cetuximab and panitumumab. Ba/F3 cells expressing EGFR G719S showed a dose-dependent … (full text at CIViC)

PMID 31290142 · Kim et al., 2020 · Open in CIViC

Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitiv… (full text at CIViC)

PMID 24894453 · Cho et al., 2014 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumum… (full text at CIViC)

PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Oncogenic somatic EGFR mutations found in colorectal cancer samples were tested for sensitivity to EGFR inhibitors cetuximab and panitumumab. Ba/F3 cells expressing EGFR K708R showed a dose-dependent … (full text at CIViC)

PMID 31290142 · Kim et al., 2020 · Open in CIViC

In vitro analysis in colorectal cancer cell line NIH3T3 with EGFR mutations S492R, R451C, K467T, and G465R showed that antibody mixture Sym004 effectively bound to all mutants, whereas cetuximab and p… (full text at CIViC)

PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

Oncogenic somatic EGFR mutations found in colorectal cancer samples were tested for sensitivity to EGFR inhibitors cetuximab and panitumumab. Ba/F3 cells expressing EGFR P596L showed a dose-dependent … (full text at CIViC)

PMID 31290142 · Kim et al., 2020 · Open in CIViC

Oncogenic somatic EGFR mutations found in colorectal cancer samples were tested for sensitivity to EGFR inhibitors cetuximab and panitumumab. Ba/F3 cells expressing EGFR R165Q showed a dose-dependent … (full text at CIViC)

PMID 31290142 · Kim et al., 2020 · Open in CIViC

Oncogenic somatic EGFR mutations found in colorectal cancer samples were tested for sensitivity to EGFR inhibitors cetuximab and panitumumab. Ba/F3 cells expressing EGFR R222C showed a dose-dependent … (full text at CIViC)

PMID 31290142 · Kim et al., 2020 · Open in CIViC

In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The R451C mutation showed moderate drug-receptor binding with sym004, cetux… (full text at CIViC)

PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

In-vitro studies found this mutation to confer resistance to cetuximab. 2 of 10 patients studied also harbored EGFR S492R and were resistant to cetuximab therapy. Panitumumab was still active in-vitro… (full text at CIViC)

PMID 22270724 · Montagut et al., 2012 · Open in CIViC

In this preclinical study of the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but re… (full text at CIViC)

PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Next-generation sequencing data of cfDNA from 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD). EGFR V441G/D/F mutations were found in 19% (n=8) of patien… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

12 CRC cell lines were evaluated. 40% of these were intrinsically resistant to mTOR inhibition with BEZ235, PP242 or WYE354. mTOR independent phosphorylation of EIF4EBP1 (T37/46) was associated with … (full text at CIViC)

PMID 22262166 · Zhang et al., 2012 · Open in CIViC

One patient with colorectal cancer harboring MSI-High and EML4-ALK rearrangement received Nivolumab and achieved a durable response.

PMID 29370427 · Pietrantonio et al., 2017 · Open in CIViC

From a retrospective review of 38,095 tumor samples from 33,997 patients using DNA sequencing (MSK-IMPACT) and RNA sequencing (MSK-Fusion panel) identified 87 tumors with NTRK1-3 fusions. Two cases of… (full text at CIViC)

PMID 31375766 · Solomon et al., 2020 · Open in CIViC

From whole exome sequencing of 278 primary colon tumors with stage I-III, 2.5% carried gene fusion. 1.5% of these were positive for kinase fusions including BRAF, NTRK3 and RET gene fusions. These gen… (full text at CIViC)

PMID 28512242 · Kloosterman et al., 2017 · Open in CIViC

Expression of EPAS1 (HIF-2alpha) was assessed in 731 colorectal cancers from two prospective cohort studies. EPAS1 overexpression was found in 322 (46%) cancers by immunohistochemistry and not signifi… (full text at CIViC)

PMID 20363910 · Baba et al., 2010 · Open in CIViC

5 out of 224 Lynch syndrome unrelated patients (2%) presented an EPCAM deletion. All patients were diagnosed with colorectal cancer (CRC) at an early age (<50 years) and had a positive family history.… (full text at CIViC)

PMID 30916491 · Cini et al., 2019 · Open in CIViC

EPHB4 expression, as assessed by quantitative RT-PCR in 13 colorectal cancer patients treated with bevacizumab, was higher in non-responders (p = 0.048). No difference was observed in a control group … (full text at CIViC)

PMID 23579861 · Guijarro-Muñoz et al., 2013 · Open in CIViC